2025-522204-24-00招募中2 期
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication
研究概览
简要总结
To compare the efficacy of LY3537021 in combination with other antiemetic treatments to placebo in combination with other antiemetic treatments
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Need treatment with an anti-cancer regimen that includes cisplatin or anthracycline and cyclophosphamide.
- •Be well enough to walk and do light work.
排除标准
- •Have had chemotherapy before.
- •Need to receive chemotherapy from Day 2 to Day 5 of each cycle.
- •Have cancer that has spread to the brain and/or spinal cord and is causing noticeable symptoms or has not yet been treated.
- •Have uncontrolled diabetes or a serious heart problem or conditions related to the heart rhythm.
- •Have another cause for nausea and vomiting, or receive medications known to prevent or treat nausea and vomiting.
- •Have signs, symptoms, or history of thyroid tumors.
- •Receive treatment with medications called incretins within 4 weeks before chemotherapy.
结局指标
主要结局
Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication
Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (4)
Loading locations...
相似试验
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
招募中
2 期
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisNCT07321873Janssen Research & Development, LLC240
招募中
1 期
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849Eli Lilly and Company141
招募中
3 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)ObesityType 2 Diabetes2022-502837-24-00Eli Lilly & Co.390
招募中
2 期
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisRheumatoid Arthritis2022-502994-40-00Eli Lilly & Co.62